Monthly Cumulative Influenza Vaccination Coverage Among Pregnant Persons, United States, 2019-2020 Compared with 2020-2021.
• These monthly flu vaccination coverage estimates for pregnant persons are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD), a collaboration between CDC’s Immunization Safety Office and nine integrated health care organizations. This system has been used annually to estimate vaccination coverage among pregnant persons.
Weekly Cumulative Influenza Vaccination Coverage, Children 6 months through 17 years, United States, 2019-2020 Compared with 2020-2021
• Influenza vaccination coverage among children is assessed through the National Immunization Survey-Flu (NIS-Flu) annually, providing weekly influenza vaccination coverage estimates for children 6 months–17 years based upon parental report. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)
o NIS-Flu is a national random-digit-dialed cellular telephone survey of households conducted during the flu season (October-June).
• Additional information about NIS-Flu methods and estimates from the 2019-2020 season are available at: https://www.cdc.gov/flu/fluvaxview/coverage-1920estimates.htm.
The bipartisan CARES Act; and the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act provided $178 billion in relief funds to hospitals and other healthcare providers on the front lines of the coronavirus response. The Department of Health and Human Services through the Health Resources and Services Administration is allocating $2 billion in incentive payments to nursing home facilities that reduce both COVID-19 infection rates relative to their county and mortality rates against a national benchmark.
The next step is to complete the RIDURA. Once complete, CDC will review your agreement. Once access is granted, ASK SRRG (email@example.com) will email you information about how to access the data through GitHub. If you have questions about obtaining access, email firstname.lastname@example.org.
The COVID-19 case surveillance system database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City, the District of Columbia, and U.S. territories. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification. The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC.
The deidentified data in the restricted access dataset include demographic characteristics (including state and county), exposure history, disease severity indicators and outcomes, clinical data, laboratory diagnostic test results, and comorbidities.
The Case Surveillance Task Force and Surveillance Review and Response Group (SRRG), within CDC’s COVID-19 Emergency Response, provides stewardship for datasets that support the public’s access to COVID-19 data while protecting individual privacy.
COVID-19 case reports have been routinely submitted using standardized case reporting forms.
On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19 included. Current versions of these case definitions are available here:
Weekly data on the number of deaths from all causes by sex, age group, and race/Hispanic origin group for the United States. Counts of deaths in more recent weeks can be compared with counts from earlier years (2015-2019) to determine if the number is higher than expected.
This data represents the age-adjusted prevalence of high total cholesterol, hypertension, and obesity among US adults aged 20 and over between 1999-2000 to 2017-2018.
* All estimates are age adjusted by the direct method to the U.S. Census 2000 population using age groups 20–39, 40–59, and 60 and over.
Hypertension: Systolic blood pressure greater than or equal to 130 mmHg or diastolic blood pressure greater than or equal to 80 mmHg, or currently taking medication to lower high blood pressure
High total cholesterol: Serum total cholesterol greater than or equal to 240 mg/dL.
Obesity: Body mass index (BMI, weight in kilograms divided by height in meters squared) greater than or equal to 30.
Data Source and Methods
Data from the National Health and Nutrition Examination Surveys (NHANES) for the years 1999–2000, 2001–2002, 2003–2004, 2005–2006, 2007–2008, 2009–2010, 2011–2012, 2013–2014, 2015–2016, and 2017–2018 were used for these analyses.
NHANES is a cross-sectional survey designed to monitor the health and nutritional status of the civilian noninstitutionalized U.S. population. The survey consists of interviews conducted in participants’ homes and standardized physical examinations, including a blood draw, conducted in mobile examination centers.
CDC is working with commercial laboratories to conduct large-scale geographic seroprevalence surveys to estimate the percentage of people who were previously infected with SARS-CoV-2, the virus that causes COVID-19 disease. The strategy involves working with state, local, territorial, academic, and commercial partners to better understand COVID-19 in the United States using serology (antibody) testing for surveillance (“seroprevalence surveys” or “serosurveys”). For the surveys, de-identified clinical blood samples are tested for antibodies to SARS-CoV-2.